The Pro Medicus Ltd (ASX: PME) share price could be on the move after the healthcare technology company announced a new 5-year, $28 million contract renewal with Allegheny Health Network and additional workflow integration.
Image source: Getty Images
What did Pro Medicus report?
- Signed a 5-year, A$28 million contract renewal with Allegheny Health Network (AHN)
- Contract includes the addition of Visage 7 Workflow with AHN
- Renewal features increased minimums and higher fee per transaction
- Brings total contract renewals for FY26 to A$125 million
- Ongoing transaction-based model with potential upside
What else do investors need to know?
Pro Medicus has maintained a strong relationship with AHN, one of the largest health networks in the Pittsburgh region, for over a decade. The inclusion of Visage 7 Workflow marks an expansion of the existing partnership, reflecting increasing demand for the company's clinical imaging solutions.
The contract continues Pro Medicus' international momentum, following consistent client retention and renewals throughout the financial year. The transaction-based model may offer further upside if imaging volumes increase.
What's next for Pro Medicus?
Pro Medicus plans to continue expanding in the North American market, leveraging its Visage 7 platform and end-to-end imaging solutions. The company is focused on client retention and attracting new health networks, aiming to boost both financial and clinical impact.
Investor attention will likely remain on contract wins and recurring revenue growth, as Pro Medicus builds on its track record of renewals and long-term partnerships.
Pro Medicus share price snapshot
Over the past 12 months, the Pro Medicus shares have declined 53%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.
